Cellect Biotechnology Ltd.’s $6.5 Million Public Offering

Sichenzia Ross Ference LLP represented A.G.P/ Alliance Global Partners as sole book running manager in the underwritten public offering of American Depository Shares (ADSs) and Warrants of Cellect Biotechnology Ltd., an Israeli biotech company (NASDAQ: APOP).

National Securities Corporation and Dawson James Securities, Inc. acted as co-managers for the offering.

The offering consisted of an aggregate of 1,889,000 units, with each unit consisting of one ADS and a warrant to purchase one ADS as well as 2,444,800 pre-funded units consisting of one pre-funded warrant and one warrant for aggregate proceeds of $6.5 million. The effective price of each unit was $1.50. Cellect has developed a breakthrough technology for the selection of stem cells from tissue that aims to improve a variety of stem cell based therapies.

The Sichenzia Ross Ference team was led by partners Gregory Sichenzia (Picture) and Avital Perlman, Counsel Jeff Cahlon and associate Grant Levine.

Involved fees earner: Jeffrey Cahlon – Sichenzia Ross Ference LLP; Grant Levine – Sichenzia Ross Ference LLP; Avital Perlman – Sichenzia Ross Ference LLP; Gregory Sichenzia – Sichenzia Ross Ference LLP;

Law Firms: Sichenzia Ross Ference LLP;

Clients: A.G.P. / Alliance Global Partners;

Print Friendly, PDF & Email

Author: Ambrogio Visconti